These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 31229334)

  • 21. Treatment of von Willebrand disease.
    Rodeghiero F; Castaman G
    Semin Hematol; 2005 Jan; 42(1):29-35. PubMed ID: 15662613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity.
    Goudemand J; Mazurier C; Marey A; Caron C; Coupez B; Mizon P; Goudemand M
    Br J Haematol; 1992 Feb; 80(2):214-21. PubMed ID: 1550779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of human recombinant, plasma-derived and porcine von Willebrand factor in pigs with severe von Willebrand disease.
    Roussi J; Turecek PL; André P; Bonneau M; Pignaud G; Bal dit Sollier C; Schlokat U; Dorner F; Schwarz HP; Drouet L
    Blood Coagul Fibrinolysis; 1998 Jun; 9(4):361-72. PubMed ID: 9690808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The factor VIII/von Willebrand factor complex: basic and clinical issues.
    Federici AB
    Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease.
    Federici AB; Mannucci PM
    Haemophilia; 1998; 4 Suppl 3():7-10. PubMed ID: 10028312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring Therapy during Treatment of von Willebrand Disease.
    Favaloro EJ; Pasalic L; Curnow J
    Semin Thromb Hemost; 2017 Apr; 43(3):338-354. PubMed ID: 27472426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial.
    Mannucci PM; Tenconi PM; Castaman G; Rodeghiero F
    Blood; 1992 Jun; 79(12):3130-7. PubMed ID: 1596562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study.
    Dunkley S; Baker RI; Pidcock M; Price J; Seldon M; Smith M; Street A; Maher D; Barrese G; Stone C; Lloyd J
    Haemophilia; 2010 Jul; 16(4):615-24. PubMed ID: 20331755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.
    Castaman G; Federici AB; Rodeghiero F; Mannucci PM
    Haematologica; 2003 Jan; 88(1):94-108. PubMed ID: 12551832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion.
    Frank RD; Kunz D; Wirtz DC
    Am J Hematol; 2002 May; 70(1):64-71. PubMed ID: 11994985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-World Efficacy and Safety of Plasma-Derived Von Willebrand Factor-Containing Factor VIII Concentrates in Patients With Von Willebrand Disease in Italy.
    Federici AB; Santoro RC; Santoro C; Pieri L; Santi RM; Barillari G; Borchiellini A; Tosetto A; Zanon E; De Cristofaro R; Mairal E; Mir R
    Clin Appl Thromb Hemost; 2024; 30():10760296241264541. PubMed ID: 39033425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Von Willebrand factor containing factor VIII concentrates.
    Berntorp E
    Haemophilia; 1999 May; 5 Suppl 2():60-3. PubMed ID: 23401902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.
    Peyvandi F; Castaman G; Gresele P; De Cristofaro R; Schinco P; Bertomoro A; Morfini M; Gamba G; Barillari G; Jiménez-Yuste V; Königs C; Iorio A; Federici AB
    Blood Transfus; 2019 Sep; 17(5):391-398. PubMed ID: 30747707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidemiology, diagnosis, and management of von Willebrand disease in India.
    Ghosh K; Shetty S
    Semin Thromb Hemost; 2011 Jul; 37(5):595-601. PubMed ID: 22102205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E; Windyga J;
    Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma.
    Lippi G; Franchini M; Salvagno GL; Montagnana M; Poli G; Guidi GC
    J Thromb Thrombolysis; 2008 Oct; 26(2):150-3. PubMed ID: 17786534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
    Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
    Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Efficacy and Safety of Fanhdi
    Jiménez-Yuste V; Alvarez-Román MT; Palomo Bravo Á; Galmes BJ; Nieto Hernández MDM; Benítez Hidalgo O; Marzo Alonso C; Pérez González NF; Coll J; Núñez R; Carrasco M; García Candel F; Gonzalez-Porras JR; Hernández García C; Varó Castro MJ; Mir R
    Clin Appl Thromb Hemost; 2022; 28():10760296221074348. PubMed ID: 35108125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.